Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 1/20 | 0.47 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 8/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2675814 | 0.93 | PSMD14 (0.53) | PSMD14MGAMABCG2EGLN1VNN1 | |
| SCHEMBL29940529 | 0.93 | PSMD14 (0.53) | PSMD14MGAMABCG2EGLN1VNN1 | |
| SCHEMBL7220371 | 0.81 | MAOB (0.48) | PSMD14MAPT | |
| SCHEMBL30547697 | 0.79 | PSMD14 (0.54) | PSMD14ABCG2VNN1 | |
| SCHEMBL7085565 | 0.79 | PSMD14 (0.54) | PSMD14ABCG2VNN1 | |
| SCHEMBL24358238 | 0.78 | PSMD14 (0.50) | PSMD14MGAMHCAR2SLC22A12 | |
| SCHEMBL1087851 | 0.78 | PSMD14 (0.64) | PSMD14MGAMEGLN1HCAR3MAPT | |
| SCHEMBL31058237 | 0.78 | PSMD14 (0.64) | PSMD14MGAMEGLN1HCAR3MAPT | |
| SCHEMBL29007074 | 0.77 | ABCG2 (0.40) | PSMD14ABCG2 | |
| SCHEMBL18987780 | 0.77 | HTT (0.49) | PSMD14MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6566362-B2 | Use as topical antibiotics | AVENTIS PHARMA S.A. (FR) | 2003-05-20 | — | — | US | disclosed |
| US-20020137741-A1 | Benzo[f]naphthyridine derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. (FR) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137741-A1 | Benzo[f]naphthyridine derivatives, their preparation and compositions containing them | KCNQ2, KCNQ1, KCNQ4 | PSMD14 1607/4885MGAM 3787/4885ABCG2 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.